Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

31.6%

12 terminated/withdrawn out of 38 trials

Success Rate

58.6%

-27.9% vs industry average

Late-Stage Pipeline

8%

3 trials in Phase 3/4

Results Transparency

100%

17 of 17 completed trials have results

Key Signals

17 with results8 terminated4 withdrawn

Enrollment Performance

Analytics

Phase 2
10(34.5%)
N/A
7(24.1%)
Phase 1
7(24.1%)
Phase 4
3(10.3%)
Early Phase 1
2(6.9%)
29Total
Phase 2(10)
N/A(7)
Phase 1(7)
Phase 4(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (38)

Showing 20 of 38 trials
NCT03960177Early Phase 1Active Not Recruiting

Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma

Role: collaborator

NCT03457948Phase 2Active Not Recruiting

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

Role: collaborator

NCT03059030Not ApplicableTerminated

Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia

Role: collaborator

NCT04105283Phase 1Completed

Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning

Role: collaborator

NCT05022797Phase 2Terminated

Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

Role: collaborator

NCT06024213Completed

A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy.

Role: lead

NCT00906984Unknown

TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma

Role: collaborator

NCT03052049Not ApplicableCompleted

Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres

Role: collaborator

NCT04046406Not ApplicableWithdrawn

Pelvic Pain Treated With MR-guided Cryoanalgesia

Role: collaborator

NCT03426124Completed

An International Pulmonary Embolism Registry Using EKOS

Role: collaborator

NCT05135858Phase 1Unknown

Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma

Role: collaborator

NCT02960620Unknown

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

Role: collaborator

NCT00746590Phase 2Terminated

Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma

Role: lead

NCT00927381Completed

Retrospective Evaluation of CroFab - Efficacy in Severe Envenomation

Role: lead

NCT00634504Phase 1Completed

Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze

Role: lead

NCT05038397Not ApplicableCompleted

A Study to Evaluate Efficacy and Safety of TheraSphere and Resection Combination Therapy in Patients With Single Large ((> 5cm, Long Diameter ) Hepatocellular Carcinoma : Exploratory Trial

Role: collaborator

NCT00511862Phase 2Completed

TheraSphere for the Treatment of Liver Metastases

Role: collaborator

NCT01428076Phase 1Completed

Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)

Role: collaborator

NCT01076517Unknown

A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma

Role: collaborator

NCT03372096Not ApplicableCompleted

LC Bead LUMI for Prostatic Artery Embolization

Role: collaborator